radioiodide in the thyroid gland. Our findings suggest that ammonium perchlorate treatment accelerates the elimination rate of radioiodide within the first 24 to 36 hours and thus may be more effective at reducing harmful exposure to 131 I − compared to KI treatment for repeated dosing situations. Repeated dosing studies are needed to compare the effectiveness of these treatments to reduce the radioactive iodide burden of the thyroid gland.
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Introduction
Stable iodide ( 127 I − ), as potassium iodide (KI) or "dietary iodine", has been recognized for over 30 years as a practical thyroid radioprotectant for people exposed to radioactive isotopes of iodide [1, 2] . In a recent National Academies of Science report on the distribution and administration of KI in the event of a nuclear incident [3] , sodium perchlorate (Irenat ® ) was recommended for adults if KI treatment was contraindicated, such as in patients with preexisting thyroid disease. Successful thyroid radioprotectant treatments, such as KI or ammonium perchlorate (NH 4 ClO 4 ), are judged by their ability to block or limit thyroidal uptake of trace amounts of radioactive iodide (e.g., into sodium iodide symporter-or pendrin-protein rich tissues, such as the thyroid and small intestine [5, [8] [9] [10] [11] [12] . Additionally, perchlorate administration displaces non-organified iodide from the thyroid, and the perchlorate discharge test has been used to diagnose iodide organification defects in humans for decades [10] . Perchlorate has been shown to have side effects ranging from rash and fever to several fatal cases of aplastic anemia [13, 14] , though these effects typically manifest from large bolus doses administered over weeks or months [15] .
Rats administered ClO 4 − intravenously (0.1-3.0 mg/kg) excreted approximately 83% of the administered ClO 4 − dose over 24 hours [16] . In a similar experiment, these authors also intravenously dosed rats with 3.3 mg/kg of isotonically labeled ClO 4 − ( 36 ClO 4 ) and reported that 96% of the dose was excreted in 24 hours and 99.5% by 48 hours [17] . In a recent study, an oral dose of 30 mg/kg of ClO 4 − was administered to rats, and 38% of the dose was recovered in urine within the first 12 hours after dosing [15] .
In the present rat study, the effectiveness of KI and NH 4 [18] . To control the potential for TSH mediated stimulation of the thyroid gland, one subset of rats for each treatment group received replacement doses of T 4 to suppress the potential for TSH release [19, 20] .
Materials and Methods

Chemicals
Ammonium perchlorate (99.8%), 100% ethanol, and sodium hydroxide were purchased from Aldrich (Milwaukee, WI, USA). Nonradioactive thyroxine was purchased from Sigma Chemical Corporation (St. Louis, MO, USA). Potassium iodide was obtained from J. T. Baker (Phillipsburg, NJ, USA), carrier-free iodide-131 ( 
Animals and Experimental Design
Male Sprague-Dawley rats (330 ± 30 g, approximately 11 weeks old) from Harlan Laboratories (Indianapolis, IN, USA) were provided LabDiet™ Laboratory Rodent Diet 5001 rat chow and water ad libitum. The animals used in this study were handled in accordance with the procedures of The University of Georgia Institutional Animal Care and Use Committee (IACUC), AUP# A2005-10110-0. The rats experienced a 12 hour light and dark cycle, with room air temperature at 22 ± 2 °C and relative humidity at 50 ± 20%.
Rats were housed individually in metabolism cages for a 5 day acclimation period prior to the start of the experiments. Twelve hours before the experiment commenced, food was removed from the animals to ensure complete absorption of the radiotracer and treatment doses. A summary of the experiments is shown in Table 1 . The general experimental protocol was to dose rats orally with 2.91 µCi (6 ng/kg) 131 I − in saline solution (1 mL) by oral gavage and then return the rats to their metabolism cages. Rats from Group 1 (n = 6 for each treatment group) were removed from their metabolism cages after 3 hours and dosed by oral gavage with 1 mL of either 0.9% saline, 30 mg/kg of KI (calculated as iodide) or 30 mg/kg of NH 4 ClO 4 (calculated as ClO 4 − ) dissolved in 0.9% aqueous saline. Rats from Group 2 (n = 6 for each treatment group) followed the same experimental protocol as Group 1 except each animal received a 0.1 mL intraperitoneal (ip) injection of 15 µg/kg of T 4 (based on euthyroid replacement T 4 doses administered by [21] ) dissolved in 0.1 M NaOH and 1 animal from each treatment group received a 0.1 mL ip injection of 0.1 M NaOH (controls). Data from animals in Group 2 that received ip injections of NaOH had not statistically different from animals of a similar treatment in Group 1. As a result, data from animals in Group 2 that received ip injections of NaOH were assimilated with animals of a similar treatment in Group 1. The rats were held in metabolism cages for 75 hours for urine collections. ), animals in Groups 1 and 2 were anesthetized with a ketamine cocktail (50 mg/kg ketamine, 3.3 mg/kg xylazine, and 3.4 mg/kg acepromazine administered at 0.1 mL per 100 g BW), then killed by asphyxiation at +75 hours. Blood was collected via cardiac puncture and serum prepared by centrifugation at 1,500 rpm at 4 °C for 15 min. Thyroid lobes were removed from the trachea and weighed. Urine was removed from the bladder via syringe. Sera, urine, and thyroid glands were stored at −80 °C until analysis. ), treated to remove proteins, and analyzed by ion chromatography electrospray ionization tandem mass spectrometry [22] . Urine samples were spiked with internal standard ( ) and analyzed by ion chromatography electrospray ionization tandem mass spectrometry [23] .
Urinary Excretion Kinetics of Anions
All urine samples for Groups 1 and 2 were analyzed for 
Statistical Analysis
Single factor analysis of variance (ANOVA) was used initially to determine significance across the treatment groups (control saline, KI and NH 4 ClO 4 ) with statistical significance set at p < 0.05. Once statistical significance was determined across the treatment groups by ANOVA, a limited number of comparisons were carried out using a two-sample t-test (assuming equal variance) to compare each treatment group (p < 0.05) to control and to each other. All calculations were performed using Microsoft Excel. It should be noted that animals in Group 2 that received ip injections of NaOH were lumped together with animals in Group 1 of a similar treatment dose, i.e., saline, KI, or ClO 4 − . collected over the 3-day period (60.5 ± 6%) was excreted in urine by 24 hours after dosing in all treatments for Groups 1 and 2 ( Figure 1(a,b) ). The 24-hour urinary excretion half-lives for Stable iodide urinary half lives determined using 24 h urine collections in rats that were treated with KI for Groups 1 and 2 were 3.5 ± 0.6 and 3.9 ± 0.3 hours respectively, with no significance between groups. Perchlorate 24 hour urinary half lives in rats that were treated with NH 4 ClO 4 for Groups 1 and 2 were 2.5 ± 0.5 and 2. 
Results
3.1.
Serum TSH Levels
The mean serum TSH concentrations for Group 1 was 4.12 ± 1.1, 4.04 ± 1.5, and 3.35 ± 1.8 ng/mL for the saline, KI, and NH 4 ClO 4 treatments, respectively. No statistical significance was determined between treatment groups. Serum TSH concentrations were below the limit of detection of the assay (1.4 ng/mL) in Group 2.
Discussion
The objective of this study was to compare the relative efficacy of stable iodide and perchlorate to purge 131 I − from the body of rats. We evaluated the efficacy of these post-exposure treatments by monitoring 131 I − in the thyroid gland, urine, and serum for up to 3 days after dosing. This study design was based on a previous study in our laboratory [15] , which showed that at 15 hours after treatment with KI or NH 4 ClO 4 , the perchlorate treated rats excreted three times the amount of (Table 2) . Interestingly, by 75 hours after dosing there was no difference in the total amount of 131 I − excreted in urine between treatment groups and the controls. This attenuation of the initial efficacy can be attributed to the short half-lives of perchlorate and iodide, 7.3 and 6 hours respectively [17, 24] , and suggests that repeated dosing with either treatment may most effectively clear 131 I − from the human body and thus protect the thyroid from radiation poisoning.
One interesting finding in this study is that rats treated with T 4 retained more thyroidal , stable iodide, or perchlorate in serum at 15 and 75 hours after dosing. Although the goal of T 4 administration was to inhibit spikes in serum TSH levels after administration of KI or NH 4 ClO 4 , the outcome was diminished serum TSH levels below euthyroid levels, thus altering the thyroid gland function. The stimulatory effect of the reduced levels of TSH in T 4 -treated rats on thyroid hormone secretion was probably very low compared with the non-T 4 treated rats, resulting in increased residual 131 I − radioactivity. The increase in residual thyroid radioactivity can likely not be attributed to the well known Wolff-Chaikoff effect given its transient nature relative to the duration of the experiment. However, the Wolff-Chaikoff effect must be considered if multiple doses of the treatments are administered over time.
The effectiveness of stable iodide and perchlorate as radioprotectants for 131 I − uptake into the thyroid gland is time-dependent [25, 26] . Zanzonico and Becker (2000) [25] determined that when KI is administered to rats 2 hours after 131 I − exposure there is an 80% reduction in uptake of radioactive iodide in the thyroid. However, when KI is administered 8 hours after 131 I − exposure the reduction in uptake of radioactive iodide is reduced by 50%. Sinadinovic and Jovanovic (1971) [26] concluded that when rats were administered perchlorate and KI 30 min or 24 hours prior to radioiodide tracer administration, the perchlorate treated animals accelerated the elimination of radioiodide from the body, reducing its systemic biological half life, compared to KI treated rats. In our experiments, the KI treated rats excreted the same total amount of radioiodide at 3 days post exposure as perchlorate treated animals, but at a slower excretion rate. We plan further experiments to evaluate the efficacy of repeated treatments of perchlorate and KI.
In conclusion, our findings suggest that stable iodide and perchlorate appear equally potent at enhancing urinary elimination of radioiodide over a 3 day period. However, the perchlorate treatment offers an accelerated elimination rate of radioiodide within the first 24 to 36 hours and has a significant reduction in the biological half-life of 131 I − in the first 24 hours. This suggests that repeated doses of perchlorate post radioiodide exposure may increase the effectiveness of blocking uptake in the thyroid and eliminating radiation in the urine. These data support continued consideration of perchlorate as a prophylactic drug to treat radioiodide poisoning. Intentional and unintentional releases of radiation remain a public health concern in many countries and more research is needed to identify the most effective therapies for protecting the thyroid from radioiodide poisoning.
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